Rafferty Asset Management LLC Grows Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Rafferty Asset Management LLC raised its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 58.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,614 shares of the company's stock after acquiring an additional 53,877 shares during the quarter. Rafferty Asset Management LLC owned about 0.19% of Kura Oncology worth $1,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC grew its position in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC bought a new position in Kura Oncology in the 4th quarter worth about $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology in the 4th quarter worth about $90,000. Corton Capital Inc. purchased a new position in Kura Oncology during the 4th quarter valued at about $99,000. Finally, Optimize Financial Inc bought a new stake in shares of Kura Oncology during the fourth quarter valued at about $100,000.

Analyst Upgrades and Downgrades

KURA has been the subject of a number of analyst reports. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. JMP Securities reiterated a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Tuesday, April 29th. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. Finally, UBS Group lowered their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Stock Performance

Kura Oncology stock opened at $6.20 on Thursday. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $536.77 million, a P/E ratio of -2.63 and a beta of 0.50. The firm's fifty day moving average price is $6.35 and its 200-day moving average price is $8.61.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. On average, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.